(Q47978464)

7 February 2018

title

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia (English)

1 reference

7 February 2018

1 reference

Montillo M

1

1 reference

7 February 2018

Mirto S

2

1 reference

7 February 2018

Petti MC

3

1 reference

7 February 2018

Latagliata R

4

1 reference

7 February 2018

Magrin S

5

1 reference

7 February 2018

Pinto A

6

1 reference

7 February 2018

Zagonel V

7

1 reference

7 February 2018

Mele G

8

1 reference

7 February 2018

Tedeschi A

9

1 reference

7 February 2018

Ferrara F

10

1 reference

7 February 2018

publication date

1 June 1998

1 reference

7 February 2018

American Journal of Hematology

published in

1 reference

7 February 2018

volume

58

1 reference

7 February 2018

issue

2

1 reference

7 February 2018

page(s)

105-109

1 reference

7 February 2018

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-8652%28199806%2958%3A2%3C105%3A%3AAID-AJH3%3E3.0.CO%3B2-W

10.1002/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

release_kbt6vy725rfevcpmrhjgd7viui

Fatcat ID

0 references

1 reference

7 February 2018